Enzalutamide

🧮 Dose calculator

Prostate cancer · Regimen source: FDA Xtandi · 2.1

• • Swallow whole. Grade ≥3 reaction: hold one week, then same or 120/80 mg. Strong CYP2C8 inhibitors: 80 mg. FDA Xtandi · 2.1FDA Xtandi · 2.2FDA Xtandi · 2.3
• • With a GnRH analogue or after bilateral orchiectomy. FDA Xtandi · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Xtandi · 8.1

  “Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Xtandi · 8.2

  “Risk Summary The safety and efficacy of XTANDI have not been established in females.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Xtandi · 8.4

  “Safety and effectiveness of XTANDI in pediatric patients have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Xtandi · 8.5

  “No overall differences in safety or effectiveness were observed between these patients and younger patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Xtandi · 8.3

  “Contraception Males Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI [see Use in Specific Populations ( 8.1 )] .”